Rockwell Medical shares surge 33.71% intraday after preliminary Q4 results show sales beat, margin improvement to 22%, and positive cash flow.

Rockwell Medical surged 33.71% intraday following the release of preliminary unaudited Q4 2025 and full-year 2025 financial results. The company reported Q4 net sales of $18.6 million, exceeding the $16.55 million consensus, and a 22% gross margin, up from 14% in Q3 2025. Positive cash flow of $2.3 million and a strengthened cash position of $25 million were highlighted, alongside full-year 2025 sales of $69.5 million. CEO Mark Strobeck emphasized operational efficiencies, profitability progress, and a strategic focus on revenue growth and diversification. The results aligned with investor expectations for improved performance, driving immediate optimism in the stock’s long-term stability and execution.